hotspot -WSS

hotspot

author：Wikipedia 2025-08-26 10:52:45 - browse：45122

3d rendered medically accurate illustration of the adrenal gland – biotech and pharma coverage from STAT — Adobe

SAN DIEGO — Neurocrine Biosciences announced on Tuesday that an experimental drug for congenital adrenal hyperplasia succeeded in a late-stage trial, bringing the company a step closer to treating patients with a rare and serious set of genetic disorders that alters their ability to produce key hormones.

In the Phase 3 study, known as CAHtalyst, 182 adults were randomly assigned to receive a placebo or crinecerfont, an oral drug Neurocrine developed to lower male sex hormones patients with the disease produce in excess. Researchers found that, compared to those on placebo, participants who took crinecerfont needed a significantly lower dose of the current standard-of-care treatment, glucocorticoids, after 24 weeks of treatment that they did at the study’s start. And about 63% of participants who took crinecerfont were able to lower their dose of glucocorticoids to levels researchers think would be safer for prolonged use, compared to 18% of those on the placebo.

Neurocine, a San Diego biotech focused on treating rare neurological and endocrine diseases, believes the drug could allow people living with congenital adrenal hyperplasia, or CAH, to avoid some of the more serious side effects of glucocorticoids by allowing them to take lower doses. Long-term use of high doses of these drugs can cause patients to gain weight and put them at risk of diabetes, heart disease, and osteoporosis.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： Study: New antibiotic targets gonorrhea as well as last existing drug

WSS

The Sacklers, horror, and ‘The Fall of the House of Usher’

The Sacklers, horror, and ‘The Fall of the House of Usher’

Biotech incubator Curie.Bio graduates its first startup

Artificial intelligence use in health care faces greater scrutiny in 2024

Congress considering partial increase for doctor pay in Medicare

Abbott's new heart device gets FDA advisory panel nod

explore

hotspot

hotspot

Malaria cases in Florida and Texas: Here’s what you need to know

Latigo launches with $135 million for Vertex

What does generative AI mean for health care? We asked experts

Extreme heat events are a public health emergency

George Santos makes 1st court appearance after pleading not guilty to 13 counts

STAT Executive Editor Rick Berke on STAT's 8th birthday

Anesthesiologist group: stop taking Ozempic before surgery

FDA approves Recor Medical high blood pressure device

United colonoscopy coverage change 'may cost lives,' doctors say

Artificial intelligence use in health care faces greater scrutiny in 2024

focus

Don't let 'shelved assets' gather dust. Make them into new lifesaving drugs

Don't let 'shelved assets' gather dust. Make them into new lifesaving drugs

Latigo launches with $135 million for Vertex

Biotech incubator Curie.Bio graduates its first startup

Why Eli Lilly’s earnings didn’t quite live up to the hype

ACIP vaccine advisory panel sees its vacancies filled

focus

focus

explore

Wikipedia